Treatment with glucagon-like peptide-1 receptor agonists (GLP-1RAs) is recommended as a second- or third-line therapeutic option for patients with inadequately controlled type 2 diabetes (T2D) [1]. Here, GLP1R is linked to type 2 diabetes mellitus.